ERBB2 and non-small cell lung carcinoma: Finally, the DESTINY-Lung04 is ongoing—a global, open-label, randomised, phase III study evaluating T-DXd vs. SoC (platinum+ pemetrexed+ pembrolizumab) as first-line treatment in patients with advanced NSCLC harbouring HER2 MUT (Ex 19 or 20) (NCT05048797).